(1R,3R)-3-phenylcyclopentanamine | 1401074-46-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (1R,3R)-3-phenylcyclopentanamine
• 英文别名: (1R,3R)-3-phenylcyclopentan-1-amine
• CAS: 1401074-46-1
• 化学式: C₁₁H₁₅N
• 分子量: 161.247
• InChiKey: ZNMXRCDHEJJIIK-GHMZBOCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (1R,3R)-3-phenylcyclopentanamine 、 (R)-7-(3-bromo-1-phenylpropyl)-N,3-ditrityl-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine 在 potassium carbonate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 7-((R)-1-phenyl-3-(((1R,3R)-3-phenylcyclopentyl)amino)propyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-amine
  参考文献：
  名称：

  Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase

  摘要：

  Myeloperoxidase (MPO) is a heme peroxidase found in neutrophils, monocytes and macrophages that efficiently catalyzes the oxidation of endogenous chloride into hypochlorous acid for antimicrobial activity. Chronic MPO activation can lead to indiscriminate protein modification causing tissue damage, and has been associated with chronic inflammatory diseases, atherosclerosis, and acute cardiovascular events. Triazolopyrimidine 5 is a reversible MPO inhibitor; however it suffers from poor stability in acid, and is an irreversible inhibitor of the DNA repair protein methyl guanine methyl transferase (MGMT). Structure-based drug design was employed to discover benzyl triazolopyridines with improved MPO potency, as well as acid stability, no reactivity with MGMT, and selectivity against thyroid peroxidase (TPO). Structure-activity relationships, a crystal structure of the MPO-inhibitor complex, and acute in vivo pharmacodynamic data are described herein.

  DOI：

  10.1016/j.bmc.2020.115723
• 作为产物：
  描述：

  (R)-3-phenyl-cyclopentylamine 在 Chiralpak AD-H 作用下， 以 hexanes 、 正己烷 、 异丙醇 为溶剂， 以44%的产率得到(1R,3R)-3-phenylcyclopentanamine
  参考文献：
  名称：

  TRPV1 Antagonists

  摘要：

  本文揭示了具有以下式（I）的化合物或药用可接受的盐、溶剂或其组合物，其中X1、X2、X3、X4、J、K、L、X5、X6、Rb、G2和m在规范中有定义。还披露了包含这些化合物的组合物以及使用这些化合物和组合物治疗疾病和疾病的方法。

  公开号：

  US20120245163A1

文献信息

• [EN] 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS<br/>[FR] 1,3-OXAZINES EN TANT QU'INHIBITEURS DE BACE1 ET/OU DE BACE2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012156284A1

  公开（公告）日：2012-11-22

  The present invention provides compounds of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明提供具有BACE1和/或BACE2抑制活性的式I化合物，它们的制备方法，含有它们的制药组合物以及它们作为治疗活性物质的用途。本发明的活性化合物可用于治疗和/或预防例如阿尔茨海默病和2型糖尿病等疾病。
• 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS
  申请人：Hilpert Hans

  公开号：US20120295900A1

  公开（公告）日：2012-11-22

  The present invention provides compounds of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明提供具有BACE1和/或BACE2抑制活性的化合物，它们的制备方法，含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗例如阿尔茨海默病和2型糖尿病方面是有用的。
• COMPLEMENT PATHWAY MODULATORS AND USES THEREOF
  申请人：Altmann Eva

  公开号：US20150141455A1

  公开（公告）日：2015-05-21

  The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了化合物I的公式：（I），本发明的化合物制备方法及其治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。
• TRPV1 ANTAGONISTS
  申请人：AbbVie Inc.

  公开号：EP2688866A1

  公开（公告）日：2014-01-29
• 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2709992A1

  公开（公告）日：2014-03-26